Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Revumenib led to high remission rates with a predictable safety profile in R/R <i>KMT2Ar</i> acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for these patients.
Authors
- Kate Madigan
- Ofir Wolach (ORCID: https://orcid.org/0000-0002-8662-0707)
- Andre C. Schuh (ORCID: https://orcid.org/0000-0003-2869-852X)
- Elie Traer (ORCID: https://orcid.org/0000-0001-8844-2345)
- Maël Heiblig (ORCID: https://orcid.org/0000-0003-1682-8657)
- Andrew H. Wei (ORCID: https://orcid.org/0000-0002-7514-3298)
- Manish R. Patel (ORCID: https://orcid.org/0000-0001-6836-2364)
- C. Michael Zwaan
- Shaun Fleming (ORCID: https://orcid.org/0000-0002-9734-5616)
- Nicole McNeer
- Martha Arellano (ORCID: https://orcid.org/0000-0003-1636-1962)
- Ashish Bajel (ORCID: https://orcid.org/0000-0002-3755-7334)
- C. Michel Zwaan (ORCID: https://orcid.org/0000-0001-6892-8268)
- Neerav Narendra Shukla (ORCID: https://orcid.org/0000-0003-2516-2965)
- Boaz Nachmias (ORCID: https://orcid.org/0000-0002-7341-2167)
- Giovanni Marconi (ORCID: https://orcid.org/0000-0001-6309-0515)
- Ioannis Mantzaris (ORCID: https://orcid.org/0000-0001-8346-5767)
- Michael J. Thirman (ORCID: https://orcid.org/0000-0001-5154-9499)
- Alexander E. Perl (ORCID: https://orcid.org/0000-0002-1463-2231)
- Ibrahim Taha Aldoss (ORCID: https://orcid.org/0000-0001-9564-4498)
- Matthew Greenwood (ORCID: https://orcid.org/0000-0002-3667-2613)
- Carolyn Grove (ORCID: https://orcid.org/0000-0003-2788-9893)
- Yakov Chudnovsky
- Branko Cuglievan (ORCID: https://orcid.org/0000-0002-6917-2244)
- Ghayas C. Issa (ORCID: https://orcid.org/0000-0002-4339-8683)
- Yu Gu (ORCID: https://orcid.org/0000-0001-8295-2141)
- John F. DiPersio (ORCID: https://orcid.org/0000-0002-0429-3133)
- Eytan M. Stein (ORCID: https://orcid.org/0000-0001-8992-9390)
- Christine M. McMahon (ORCID: https://orcid.org/0000-0001-9745-9595)
- Richard Maury Stone (ORCID: https://orcid.org/0000-0002-7526-2633)
- David S. Dickens (ORCID: https://orcid.org/0000-0001-8821-6022)
- Nguyễn Văn Huy (ORCID: https://orcid.org/0000-0002-5896-9661)
- Chetasi Talati (ORCID: https://orcid.org/0000-0002-2246-213X)
- John Byrd
- James S. Blachly (ORCID: https://orcid.org/0000-0002-4275-5562)
- James A. Whitlock (ORCID: https://orcid.org/0000-0002-7887-0634)
- Gabriel N. Mannis
- Jing Chen (ORCID: https://orcid.org/0000-0001-6695-3013)
- Paul J. Shami (ORCID: https://orcid.org/0000-0002-5696-6512)
- Himalee Sabins
- Montserrat Arnan-Sangerman
- Tibor Kovacsovics (ORCID: https://orcid.org/0000-0003-3294-0761)
- Rebecca G. Bagley
- P Fernandez
- Paul J. Shami
Institutions
- The University of Sydney (AU)
- Albert Einstein College of Medicine (US)
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Montefiore Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- Oregon Health & Science University (US)
- Washington University in St. Louis (US)
- University of Utah (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Royal North Shore Hospital (AU)
- Huntsman Cancer Institute (US)
- Sir Charles Gairdner Hospital (AU)
- University of Chicago (US)
- University of Colorado Health (US)
- University of Iowa Stead Family Children’s Hospital (US)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- Princess Máxima Center (NL)
- Erasmus MC - Sophia Children’s Hospital (NL)
- Goodyear (United States) (US)
- Synta Pharmaceuticals (United States) (US)
- Montefiore Einstein Comprehensive Cancer Center
- The Ohio State University (US)
- University of Pennsylvania (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1200/jco.24.00826
- Citations
- 150
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 68.16
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Yale University
- Gilead Sciences
- Celgene
- Carnegie Mellon University
- Foghorn Therapeutics
- Agios Pharmaceuticals
- CTI Biopharma
- Incyte
- Calithera Biosciences
- Syndax Pharmaceuticals
- Eisai
- Astellas Pharma
- Genesis Pharma
- Servier
- Ono Pharmaceutical
- Genentech
- Daiichi Sankyo Europe